# Pembrolizumab and All-Trans Retinoic Acid Combination Treatment of Advanced Melanoma

> **NCT03200847** · PHASE1,PHASE2 · COMPLETED · sponsor: **University of Colorado, Denver** · enrollment: 26 (actual)

## Conditions studied

- Stage IV Melanoma
- Stage III Melanoma
- Advanced Melanoma

## Interventions

- **DRUG:** Pembrolizumab with All-Trans Retinoic Acid

## Key facts

- **NCT ID:** NCT03200847
- **Lead sponsor:** University of Colorado, Denver
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2017-10-31
- **Primary completion:** 2022-07-20
- **Final completion:** 2022-10-19
- **Target enrollment:** 26 (ACTUAL)
- **Last updated:** 2024-10-01

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03200847

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03200847, "Pembrolizumab and All-Trans Retinoic Acid Combination Treatment of Advanced Melanoma". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT03200847. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*